Skip to main content

For US Healthcare Professionals only

Beyfortus® logo
For OB-GYNS
Dosing & Administration

Request a Representative

Connect with a Sanofi representative

Get personalized support, product information, and answers to your questions about prevention of RSV lower respiratory disease in infants and certain children.

Need immediate support? Call us at 1-800-VACCINE.

All fields are required unless noted as optional.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection?
Leave us your contact details, and a Sanofi representative will be in touch.

All fields are required.

By submitting the following information, you are acknowledging that you understand that the information you provide may be used by Sanofi and their affiliates, and the business service companies working with Sanofi, to provide you with additional communications and to develop products and services, which may include market research.

Sanofi respects your interest in keeping your personal health information private. We will not sell or rent your information to any third parties or outside mailing lists.

You may have certain rights under applicable data privacy laws regarding the personal information that you provide to Sanofi, including the right to access your personal information held by Sanofi. For further information regarding these rights, please reference our Privacy Policy.

Call us

For more information about Beyfortus®, contact us at 1-855-BEYFORTUS (1-855-239-3678).

Ordering Beyfortus

For ordering questions or information, contact 1-800-VACCINE (1-800-822-2463).

Medical information

For medical questions or concerns, please contact the medical information team at 1-800-633-1610.

RSV, respiratory syncytial virus.

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Important Safety Information

Indication

MAT-US-2504779-v5.0-08/2026

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.